Dr. Christiansen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2405 Shadelands Dr
Ste 300
Walnut Creek, CA 94598Phone+1 925-939-8585
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1990
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1985 - 1988
- Case Western Reserve University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1988 - 2025
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism Start of enrollment: 2011 Sep 01
- A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 3 citationsReduction in Postprandial Peak Glucose With Increased Technosphere Insulin Dosage.Kevin B Kaiserman, Mark Christiansen, Sunil Bhavsar, Johanna Ulloa, Brandi Santogatta
Journal of Diabetes Science and Technology. 2024-03-01 - 12 citationsGlycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.Toni L Cordero, Zheng Dai, Arcelia Arrieta, Fang Niu, Melissa Vella
Diabetes Technology & Therapeutics. 2023-09-01 - 16 citationsAccuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes.Lori M Laffel, Timothy S Bailey, Mark P Christiansen, Jennifer L Reid, Stayce E Beck
Journal of Diabetes Science and Technology. 2023-07-01
Press Mentions
- Abbott, Medtronic Go Head-to-Head at ADA ConferenceJune 15th, 2020
- Senseonics Announces First Study Participant Implanted in the U.S. As Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day ProductJanuary 3rd, 2019
- Senseonics Maakt Uitstekende Nauwkeurigheidsresultaten Bekend Uit Hoofdstudie Eversense CGM-Systeem in VSAugust 10th, 2016
- Join now to see all
Grant Support
- Hepatic Insulin Resistance Associated With The Use Of PINational Center For Research Resources2000–2002
- Effects Of Etiocholanedione On Hepatic Metabolism &Insulin ResistancNational Center For Research Resources1999–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: